NEW INSIGHTS INTO DIAGNOSIS AND THERAPEUTIC MODULATION OF DRUG-INDUCED HEPATOTOXICITY

Authors

  • Liliana MITITELU-TARTAU “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
  • Paraschiva POSTOLACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
  • R. DMOUR “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
  • Allia SINDILAR
  • A.C. PINZARIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
  • Beatrice ROZALINA “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
  • Nicoleta-Loredana HILITANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

Abstract

NEW INSIGHTS INTO DIAGNOSIS AND THERAPEUTIC MODULATION OF DRUG-INDUCED HEPATOTOXICITY (Abstract): Drug-induced hepatotoxicity may be the consequence of numerous drugs and chemical compounds, such as antimicrobial agents, anticonvulsant drugs, antineoplastic medication, herbal medicines and dietary supplements. The early and correct diagnosis of the drug-induced liver injury is an important aspect that allows for adequate therapy and the possibility of assessing the severity and prognosis of this pathological condition. Currently, the variations of serum transaminase, alkaline phosphatase and total bilirubin values, represent usual, but suboptimal laboratory parameters for the identification of presence, severity and the evolution of liver damage. Some biomarkers such as: apoptotic index, glutamate dehydrogenase, high mobility group box 1 protein and microRNA-122, are recently considered the valuable candidates in assessing the drug induced liver injury. A lot of active substances: chitosan, quercetin, collagen, citral, have been extensively investigated and proved hepatoprotective, antioxidant and anti-inflammatory effects during the in vitro and in vivo researches. The use of different compounds based on biocompatible polymers and natural substances represents a generous research direction and provides interesting perspective on development of innovative hepatoprotective agents.

Author Biographies

  • Liliana MITITELU-TARTAU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Paraschiva POSTOLACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Faculty of Medicine
    Department of Medical Specialties (I)
    Clinical Rehabilitation Hospital, Iasi

  • R. DMOUR, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Allia SINDILAR

    Faculty of Medicine
    Department of Morpho-functional Sciences (I)

  • A.C. PINZARIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Faculty of Medicine
    Department of Morpho-functional Sciences (I)

  • Beatrice ROZALINA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Faculty of Medicine
    Department of Morpho-functional Sciences (II)

  • Nicoleta-Loredana HILITANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania

    Clinical Rehabilitation Hospital, Iasi

References

1. Cojocariu CE, Trifan AV, Gîrleanu I, et al. Alcoholic liver disease-epidemiology and risk factors. Rev Med Chir Soc Med Nat Iasi 2014; 118(4): 910-917.
2. Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci 2017; 18: pii: E1018.
3. Sutti S, Tacke F. Liver inflammation and regeneration in drug-induced liver injury: sex matters! Clin Sci 2018; 132: 609-613.
4. Livadariu R, Timofte D, Dănilă R, et al. Nonalcoholic fatty liver disease and its complications - assessing the population at risk. A small series report and literature review. Rev Med Chir Soc Med Nat Iasi 2015; 119(2): 346-352.
5. Teschke R, Danan G. Molecular research on drug induced liver injury. Int J Mol Sci 2018; 19, 216: 2-5.
6. Navarro V, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017; 65(1): 363-373.
7. Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-1164.
8. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018; 31(6): 965-973.
9. Marrone G, Vaccaro FG, Biolato M, et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci 2017; 21(1 Suppl): 122-134.
10. Watkins PB. Biomarkers for drug-induced liver injury. Therapy 2010; 7(4): 367-375.
11. Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int 2017; 37(11): 1582-1590.
12. Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology 2018; doi: 10.1002/hep.29802.
13. Antoine DJ, Dear JW. Transformative biomarkers for drug-induced liver injury: are we there yet? Biomark Med 2017; 11(2): 103-106.
14. Dear JW. New biomarkers for drug-induced liver injury. Hepatology 2018; 67(6): 2480-2481.
15. Năftănăilă-Mali F, Negoiță IA, Soloman DE, et al. The evaluation of hepatoprotective effect of si-lymarin, Phyllanthus niruri extract and choline combination. Rev Med Chir Soc Med Nat Iasi 2018; 122(2): 267-275.
16. Madrigal-Santillán E, Madrigal-Bujaidar E, Álvarez-González I, et al. Review of natural products with hepatoprotective effects. World J Gastroenterol 2014; 20(40): 14787-14804.
17. Domitrović R, Potočnjak I. A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives. Arch Toxicol 2016; 90(1): 39-79.
18. Postolache P, Petrescu V, Dumitrascu DD, et al. Research Regarding a Correlation Core-Shell Mor-phology-Termal Stability of Silica-Silver Nanoparticles. Chem Eng Comm 2016; 203(5): 649-659.
19. Ozcelik E, Uslu S, Erkasap N, et al. Protective effect of chitosan treatment against acetaminophen-induced hepatotoxicity. KJMS 2014; 30(6): 286-290.
20. Abdelhakim MA, Radwan MS, Rady AH. Chitosan nanoparticles as hepato-protective agent against alcohol and fatty diet stress in rats. Biochem Int 2017; 4(1): 5-10.
21. Santhosh S, Sini TK, Anandan R, et al. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur J Pharmacol 2007; 572(1): 69-73.
22. Barros PP, da Silva GH, Gonçalves GMS, et al. Hepatoprotective effect of quercetin pretreatment against paracetamol-induced liver damage and partial hepatectomy in rats. Braz Arch Biol Technol 2017; v.60: e17160138.
23. Ansar S, Siddiqi NJ, Zargar S, et al. Hepatoprotective effect of quercetin supplementation against acrylamide-induced DNA damage in wistar rats. BMC Complement Altern Med 2016; 16(1): 327-332.
24. Eftekhari A, Ahmadian E, Panahi-Azar V, et al. Hepatoprotective and free radical scavenging actions of quercetin nanoparticles on aflatoxin B1-induced liver damage: in vitro/in vivo studies. Artif Cells Nanomed Biotechnol 2018; 46(2): 411-420.
25. El-Denshary ES, Aljawish A, El-Nekeety AA, et al. Possible synergistic effect and antioxidant prop-erties of chitosan nanoparticles and quercetin against carbon tetrachloride-induce hepatotoxicity in rats. Soft Nanosci Lett, 2015; 5: 36-51.
26. Lin B, Zhang F, Yu Y, et al. Marine collagen peptides protect against early alcoholic liver injury in rats. Br J Nutr 2012; 107(8): 1160-1166.
27. Han Y, Xie J, Gao H, et al. Hepatoprotective effect of collagen peptides from cod skin against liver oxidative damage in vitro and in vivo. Cell Biochem Biophys 2015; 71(2): 1089-1095.
28. Uchida NS, Silva-Filho SE, Cardia GFE, et al. Hepatoprotective effect of citral on acetaminophen-induced liver toxicity in mice. J Evid Based Complementary Altern Med 2017; ID 1796209, 1-9.
29. Li CC, Yu HF, Chang CH, et al. Effects of lemongrass oil and citral on hepatic drug-metabolizing enzymes, oxidative stress, and acetaminophen toxicity in rats. JFDA 2018; 26(1): 432-438.
30. Kus K, Walczak M, Maslak E, et al. Hepatoselective nitric oxide (NO) donors, V-PYRRO/NO and V-PROLI/NO, in nonalcoholic fatty liver disease: a comparison of antisteatotic effects with the bio-transformation and pharmacokinetics. Drug Metab Dispos 2015; 43(7): 1028-1036.
31. Kus E, Jasiński K, Skórka T, et al. Short-term treatment with hepatoselective NO donor V-PYRRO/NO improves blood flow in hepatic microcirculation in liver steatosis in mice. Pharmacol Rep 2018; 70(3): 463-469.

Additional Files

Published

2019-03-29

Issue

Vol. 123 No. 1 (2019): The Medical-Surgical Journal

Section

INTERNAL MEDICINE - PEDIATRICS

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form